Hepion Pharmaceuticals (HEPA) Competitors $0.05 -0.01 (-11.67%) As of 09/24/2025 02:41 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock HEPA vs. GLMD, UPC, ATXI, ELAB, CDT, CANF, SLRX, SPRC, WINT, and ENVBShould you be buying Hepion Pharmaceuticals stock or one of its competitors? The main competitors of Hepion Pharmaceuticals include Galmed Pharmaceuticals (GLMD), Universe Pharmaceuticals (UPC), Avenue Therapeutics (ATXI), PMGC (ELAB), CDT Equity (CDT), Can-Fite BioPharma (CANF), Salarius Pharmaceuticals (SLRX), SciSparc (SPRC), Windtree Therapeutics (WINT), and Enveric Biosciences (ENVB). These companies are all part of the "pharmaceutical products" industry. Hepion Pharmaceuticals vs. Its Competitors Galmed Pharmaceuticals Universe Pharmaceuticals Avenue Therapeutics PMGC CDT Equity Can-Fite BioPharma Salarius Pharmaceuticals SciSparc Windtree Therapeutics Enveric Biosciences Hepion Pharmaceuticals (NASDAQ:HEPA) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation. Do analysts prefer HEPA or GLMD? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hepion Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Galmed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals and insiders believe in HEPA or GLMD? 17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. 0.1% of Hepion Pharmaceuticals shares are owned by insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more risk and volatility, HEPA or GLMD? Hepion Pharmaceuticals has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500. Comparatively, Galmed Pharmaceuticals has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Which has better valuation & earnings, HEPA or GLMD? Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHepion PharmaceuticalsN/AN/A-$48.93M-$219.000.00Galmed PharmaceuticalsN/AN/A-$7.52M-$16.66-0.09 Is HEPA or GLMD more profitable? Galmed Pharmaceuticals' return on equity of -20.69% beat Hepion Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Hepion PharmaceuticalsN/A -812.56% -207.31% Galmed Pharmaceuticals N/A -20.69%-18.41% Does the media favor HEPA or GLMD? In the previous week, Galmed Pharmaceuticals had 1 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 1 mentions for Galmed Pharmaceuticals and 0 mentions for Hepion Pharmaceuticals. Hepion Pharmaceuticals' average media sentiment score of 0.00 equaled Galmed Pharmaceuticals'average media sentiment score. Company Overall Sentiment Hepion Pharmaceuticals Neutral Galmed Pharmaceuticals Neutral SummaryGalmed Pharmaceuticals beats Hepion Pharmaceuticals on 8 of the 10 factors compared between the two stocks. Get Hepion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for HEPA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HEPA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HEPA vs. The Competition Export to ExcelMetricHepion PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$606K$845.08M$5.70B$10.23BDividend YieldN/A4.84%5.68%4.61%P/E Ratio-0.011.1776.0426.13Price / SalesN/A25.65516.68165.77Price / CashN/A17.6537.5661.52Price / Book0.046.4512.676.32Net Income-$48.93M-$5.56M$3.29B$270.94M7 Day PerformanceN/A-0.06%0.09%-0.10%1 Month PerformanceN/A5.51%4.14%6.37%1 Year PerformanceN/A28.75%65.69%28.45% Hepion Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HEPAHepion PharmaceuticalsN/A$0.05-11.7%N/A-99.8%$606KN/A-0.0120Gap DownHigh Trading VolumeGLMDGalmed Pharmaceuticals0.6875 of 5 stars$1.51+2.4%N/A-82.1%$2.50MN/A-0.0920UPCUniverse Pharmaceuticals0.7127 of 5 stars$4.39-1.1%N/AN/A$2.46M$23.02M0.00220Gap DownATXIAvenue Therapeutics1.221 of 5 stars$0.760.0%N/A-64.4%$2.42MN/A0.044ELABPMGC0.271 of 5 stars$5.71+1.4%N/A-98.9%$2.36M$1.71M-0.0118CDTCDT Equity0.3234 of 5 stars$0.78+3.1%N/A-99.6%$2.36MN/A0.003CANFCan-Fite BioPharma1.7638 of 5 stars$0.63-0.4%$14.50+2,194.3%-69.7%$2.24M$560K-0.358SLRXSalarius Pharmaceuticals0.0583 of 5 stars$4.29+2.0%N/A-82.6%$2.19MN/A-0.1020SPRCSciSparc0.4661 of 5 stars$4.12+3.8%N/A-28.2%$2.18M$1.31M0.004News CoverageGap UpTrading HaltedWINTWindtree Therapeutics1.74 of 5 stars$0.07-7.4%$350.00+510,848.9%-100.0%$2.01MN/A0.0030Gap DownENVBEnveric Biosciences1.7519 of 5 stars$0.60+2.2%$10.00+1,580.7%-91.7%$1.93MN/A-0.0220Gap Up Related Companies and Tools Related Companies GLMD Alternatives UPC Alternatives ATXI Alternatives ELAB Alternatives CDT Alternatives CANF Alternatives SLRX Alternatives SPRC Alternatives WINT Alternatives ENVB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HEPA) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hepion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hepion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HEPA Stock Alerts